
Genentech Highlights New Lunsumio Data in Lymphomas
Genentech Highlights Lunsumio’s Expanding Potential Across Multiple Lymphoma Treatment Lines at ASH 2025 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented compelling new clinical data at the 67th American Society of Hematology (ASH) Annual…












